The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: dsDNA virus peptides. Buy the report here.

Smarter leaders trust GlobalData

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

110 innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

dsDNA virus peptides are a key innovation area in pharmaceutical

Double-stranded DNA (dsDNA) viruses package their genomic DNA into a procapsid using an ATP-powered nanomotor. According to some studies, the peptide, which is a short chain of amino acids, acts at the early stages of infection upon or immediately after virus entry and has antiviral activity through selective inhibition of viral gene expression, while only transiently altering cellular genes, which are activated in response to viral infection. The peptide, therefore, offers a promising approach to developing a broad-spectrum antiviral drug against double-stranded DNA viruses.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 140+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of dsDNA virus peptides.

Key players in dsDNA virus peptides – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local.’

Patent volumes related to dsDNA virus peptides

Company Total patents (2021 - 2023) Premium intelligence on the world's largest companies
GSK 285 Unlock Company Profile
Johnson & Johnson 259 Unlock Company Profile
Merck & Co 234 Unlock Company Profile
Precigen 123 Unlock Company Profile
Hologic 113 Unlock Company Profile
Xiamen Innovax Biotech 107 Unlock Company Profile
Advaxis 82 Unlock Company Profile
City of Hope 75 Unlock Company Profile
Calliditas Therapeutics 52 Unlock Company Profile
Replimune Group 50 Unlock Company Profile
German Cancer Research Center 48 Unlock Company Profile
Compagnie Merieux Alliance 48 Unlock Company Profile
AstraZeneca 43 Unlock Company Profile
Minapharm Pharmaceuticals 43 Unlock Company Profile
BioNTech 42 Unlock Company Profile
Pfizer 40 Unlock Company Profile
TheVax Genetics Vaccine 40 Unlock Company Profile
Hookipa Pharma 39 Unlock Company Profile
FDS Pharma LLP 36 Unlock Company Profile
Yangshengtang 34 Unlock Company Profile
Cedars-Sinai Health System 34 Unlock Company Profile
Institut Catala d'Oncologia 33 Unlock Company Profile
Mayo Clinic 31 Unlock Company Profile
Meiji Holdings 31 Unlock Company Profile
Helmholtz Association of German Research Centres 31 Unlock Company Profile
Inovio Pharmaceuticals 31 Unlock Company Profile
Cue Biopharma 31 Unlock Company Profile
Nouscom 31 Unlock Company Profile
GenVivo 30 Unlock Company Profile
Walvax Biotechnology 28 Unlock Company Profile
Etubics 27 Unlock Company Profile
Nykode Therapeutics 25 Unlock Company Profile
C. H. Boehringer Sohn 25 Unlock Company Profile
F. Hoffmann-La Roche 24 Unlock Company Profile
Massachusetts General Hospital 24 Unlock Company Profile
Fresh Tracks Therapeutics 24 Unlock Company Profile
Grifols 23 Unlock Company Profile
Yamaha Motor 22 Unlock Company Profile
Angiocrine Bioscience 20 Unlock Company Profile
TRON gGmbH 20 Unlock Company Profile
Intima Bioscience 19 Unlock Company Profile
Agenus 18 Unlock Company Profile
Moderna 18 Unlock Company Profile
Anteris Technologies 18 Unlock Company Profile
Toscana Biomarkers 18 Unlock Company Profile
Fred Hutchinson Cancer Research Center 17 Unlock Company Profile
Sanofi 17 Unlock Company Profile
Centre National de la Recherche Scientifique 17 Unlock Company Profile
Inventprise 16 Unlock Company Profile
Jingang Medicine (Australia) 16 Unlock Company Profile

Source: GlobalData Patent Analytics

GSK is the leading patent filer in dsDNA virus peptides. GSK is a healthcare company which focuses on developing, manufacturing and commercialising pharmaceuticals, vaccines, and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular, and urogenital, anti-bacterials, dermatology and rare diseases. GSK’s drug Benlysta is indicated as an add-on therapy in patients aged five years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (for example, positive anti-dsDNA and low complement) despite standard therapy. Johnson & Johnson and Merck are the other key patent filers in dsDNA virus peptides.

In terms of application diversity, IMV is the top company, followed by Assistance Publique - Hopitaux de Paris and Obetech By means of geographic reach, BioNTech holds the top position. Bharat Biotech and AstraZeneca stand in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.